GBLX - GB Sciences, Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
0.3075
-0.0125 (-3.91%)
As of 10:48AM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close0.3200
Open0.3090
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.3004 - 0.3200
52 Week Range0.2100 - 1.5600
Volume317,102
Avg. Volume1,329,361
Market Cap61.959M
Beta-2.34
PE Ratio (TTM)N/A
EPS (TTM)-0.1720
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • GB Sciences Hosts Cutting-Edge Cannabis Symposium "Innovation in Medical Cannabis Therapies"
    PR Newswire4 days ago

    GB Sciences Hosts Cutting-Edge Cannabis Symposium "Innovation in Medical Cannabis Therapies"

    LAS VEGAS, Sept. 20, 2018 /PRNewswire/ -- GB Sciences, Inc. (GBLX)  has mobilized cannabis industry thought leaders to discuss both the immense potential for cannabis-based therapies and the challenges of delivering on their medical promise under state regulated programs at their fourth annual "Innovation in Medical Cannabis Therapies" symposium on November 9th at the "Keep Memory Alive" Event Center at the Cleveland Clinic's Lou Ruvo Center for Brain Health in Las Vegas, NV. This event has attracted innovative leaders in cannabis biotech, nanotech, metabolomics, cultivation and extraction tech.  GB Sciences is pleased to announce this will include representatives from US and international research universities, cannabis industry leaders, clinical research organizations, and cannabis tech companies.

  • GB Sciences' Dr. Andrea Small-Howard, Chief Science Officer, Will Be Moderating a Panel Discussion in "Cannabis Is Medicine" at the "State of Cannabis" Conference on the Queen Mary
    PR Newswire6 days ago

    GB Sciences' Dr. Andrea Small-Howard, Chief Science Officer, Will Be Moderating a Panel Discussion in "Cannabis Is Medicine" at the "State of Cannabis" Conference on the Queen Mary

    Dr. Andrea Small-Howard is featured in the "Meeting of the Minds" at the two-day educational conference hosted on the historic Queen Mary. LAS VEGAS, Sept. 18, 2018 /PRNewswire/ -- GB Sciences, Inc. (GBLX) announces that Dr. Andrea Small-Howard will be moderating the panel discussion which kicks-off the "Cannabis Is Medicine Track" and explores important Research Initiatives. Of great interest to this panel is The Medical Cannabis Research Act of 2018, which was unanimously approved by the House Judiciary Committee with widespread bipartisan support on September 13th.

  • The State of Louisiana Pharmacy Board Has Selected Nine Initial Pharmacies to Dispense Medical Cannabis Formulations Through the GB Sciences and LSU Agriculture Center Partnership
    PR Newswirelast month

    The State of Louisiana Pharmacy Board Has Selected Nine Initial Pharmacies to Dispense Medical Cannabis Formulations Through the GB Sciences and LSU Agriculture Center Partnership

    In Partnership with GB Sciences and LSU AgCenter, Nine Select Louisiana Pharmacies Are Set to Pioneer the Louisiana Medical Cannabis Program. BATON ROUGE, La. , Aug. 23, 2018 /PRNewswire/ -- GB Sciences, ...

  • GB Sciences and Louisiana State University Agricultural Center Begins Cultivation of Their First Cannabis Crop
    PR Newswirelast month

    GB Sciences and Louisiana State University Agricultural Center Begins Cultivation of Their First Cannabis Crop

    The first plants generated through tissue culture have now moved into their environmentally controlled cannabis grow pod. BATON ROUGE, La., Aug. 21, 2018 /PRNewswire/ -- GB Sciences, Inc. (GBLX) and the LSU Agricultural Center (LSU AgCenter), have now commenced operation in the environmentally controlled grow pod. Representatives from nine Louisiana pharmacies authorized to dispense medical cannabis toured our high-tech 36,000-sq ft GB Sciences facility in Baton Rouge, LA.

  • GlobeNewswirelast month

    GB Sciences reports first quarter revenue of $1.3 million with gross profit of $700 thousand compared to revenue of $69,100 for same period last year

    For the three months that ended June 30, 2018, GB Sciences, Inc. (GBLX) reported revenue of $1,315,284 and gross profit of  $734,719.  This compares to revenue and gross profit of $69,100 and $54,099, respectively, for the same period the prior year. The Company's goal is creating safe, standardized, pharmaceutical-grade, cannabinoid therapies that target a variety of medical conditions. To learn more about GB Sciences, Inc., go to: http://gbsciences.com.

  • Michigan State University's Dr. Norbert Kaminski Begins Pre-Clinical Study of GB Sciences' Neuroprotective Cannabis Compounds For Parkinson's Disease
    PR Newswire2 months ago

    Michigan State University's Dr. Norbert Kaminski Begins Pre-Clinical Study of GB Sciences' Neuroprotective Cannabis Compounds For Parkinson's Disease

    This pre-clinical study examines the Immunotoxicology and anti-inflammatory properties of GB Sciences' Cannabis-Containing Complex Formulas for Parkinson's Disease in preparation for their clinical trial. LAS VEGAS, Aug. 6, 2018 /PRNewswire/ -- GB Sciences, Inc. (GBLX) has signed an agreement to initiate research collaborations with Dr. Norbert Kaminski, Professor of Pharmacology & Toxicology at Michigan State University. Dr. Kaminski will study the toxicology, anti-inflammatory properties, and immunomodulatory activity of GB Sciences' proprietary cannabis-based neuroprotective compounds using a diverse array of assays employing human primary white blood cells.

  • GB Sciences Co-Authors a Peer Reviewed Article Published in the Journal of the American Heart Association Titled: "Cannabinoids, The Heart of the Matter"
    PR Newswire2 months ago

    GB Sciences Co-Authors a Peer Reviewed Article Published in the Journal of the American Heart Association Titled: "Cannabinoids, The Heart of the Matter"

    This pioneering research article explains the benefits of cannabinoid-based medicines for heart disease therapies based on scientific research. LAS VEGAS, Aug. 2, 2018 /PRNewswire/ -- GB Sciences, Inc. (GBLX) is pleased to announce the publication of a review article co-authored by GB Sciences and key collaborators in the Journal of the American Heart Association, which explains the potential medical benefits of using cannabinoid-based therapies for the treatment of heart diseases. GB Sciences' own Chief Science Officer, Dr. Andrea Small-Howard, joins co-authors including Dr. Alexander Stokes, President of Makai Biotechnology, LLC, and Dr. Helen Turner, VP of Innovation and Dean of the Division of Natural Sciences and Mathematics at Chaminade University, in expounding on this very important subject in "Cannabinoids, the Heart of the Matter".

  • GlobeNewswire2 months ago

    GB Sciences Strengthen Their Current and Future Compliance Programs by Building A Relationship with Adherence Compliance

    GB Sciences, Inc (GBLX) has contracted Adherence Compliance, a leading cannabis compliance software and services firm, for its Chief Compliance Officer Program and Adherence SCORE App (a leading cannabis industry compliance inspection tool) to strengthen overall compliance in all U.S. markets where GB Sciences is currently operating or planning to initiate operations.  “GB Sciences is continually focused on strengthening our enterprise compliance, especially given our aggressive expansion plans and the constantly changing regulatory landscape” said Dr. Dominick Monaco, VP Operations for GB Sciences.

  • GB Sciences Partners with the Colorado Hemp Project to Cultivate and Extract Full Spectrum Hemp Oil from Proprietary Hemp Strains to Open a New Revenue Stream in the Rapidly Growing Hemp Market
    PR Newswire2 months ago

    GB Sciences Partners with the Colorado Hemp Project to Cultivate and Extract Full Spectrum Hemp Oil from Proprietary Hemp Strains to Open a New Revenue Stream in the Rapidly Growing Hemp Market

    The first six proprietary strains are being cultivated by The Colorado Hemp Project and will serve as the basis for fresh revenue streams from both retail sales and raw ingredients for cannabis-based medical formulations. LAS VEGAS, July 16, 2018 /PRNewswire/ -- GB Sciences, Inc. (GBLX) updates the progress in their efforts to identify, cultivate and extract full spectrum hemp oil from proprietary hemp strains that contain desirable ratios of CBD, cannabinoids and terpenes to provide the necessary compounds to support both the Company's medical Intellectual Properties portfolio and open a fresh revenue stream in the rapidly growing retail hemp market. The search for a full spectrum hemp oil product that matched the quality and consistency of their cannabis genetics led GB Sciences to The Colorado Hemp Project.

  • GB Sciences One of Ten Companies Named in Important New Canadian Research Publication
    PR Newswire3 months ago

    GB Sciences One of Ten Companies Named in Important New Canadian Research Publication

    LAS VEGAS, July 9, 2018 /PRNewswire/ -- GB Sciences, Inc. (GBLX) was named as one of the ten select cannabis companies in North America according to a study conducted by a leading investment banking firm in their June 20, 2018 Industry Report on Medical Cannabis. GB Sciences was the only U.S. publicly traded company to make the list of ten companies.

  • GlobeNewswire3 months ago

    GB Sciences Files Patent on Cannabis-based Therapies for the Treatment of Asthma, Urinary Cystitis, Hearing Loss, plus Chronic, Inflammatory and Neuropathic Pain

    GB Sciences, Inc. (GBLX) has filed a new provisional patent application on the use of cannabis-based therapies for the manipulation of cannabis-sensitive ion channels in sensory neurons that contribute to chronic inflammatory pain conditions, peripheral neuropathy, urinary cystitis, asthma, and specific types of hearing loss. The GB Sciences drug development team believes that these new cannabis-based treatments could well herald the dawning of ‘individualized medicines’ from the cannabis plant by re-establishing balance in each individual patient’s endocannabinoid system. “Manipulating the TRP channels in sensory neurons could provide much needed relief for patients who are suffering from chronic pain, asthma, urinary cystitis, or hearing loss,” explains Dr. Andrea Small-Howard, Chief Science Officer of GB Sciences.

  • GB Sciences Files Patents for Heart Disease and Chronic, Immunological, and Neuropathic Pain
    PR Newswire3 months ago

    GB Sciences Files Patents for Heart Disease and Chronic, Immunological, and Neuropathic Pain

    The nonprovisional patent applications protect formulations for pain and heart disease therapies based on myrcene-containing complex mixtures. LAS VEGAS , June 25, 2018 /PRNewswire/ -- GB Sciences, Inc. ...

  • PR Newswire4 months ago

    GB Sciences Will Now Serve A Greatly Expanded Patient Base In Louisiana With The Addition Of Autism, Glaucoma, Parkinson's, PTSD, Intractable Pain And Severe Muscle Spasms To The List Of Ailments Covered By Medical Cannabis Legislation

    LAS VEGAS, May 22, 2018 /PRNewswire/ -- GB Sciences, Inc. (GBLX), it all started with one woman's plea and ended with a call to action for a dramatic expansion of diseases treated by medical cannabis throughout the State of Louisiana. The passage of the Alison Neustrom Act in 2015 opened the door for a relatively small number of qualified patients to legally receive medical marijuana treatment. The passage of two new House Bills increases the patient count to include patients with additional qualifying disease conditions in the State.

  • GB Sciences' Acquisition Of NevadaPURE Is Terminated
    PR Newswire5 months ago

    GB Sciences' Acquisition Of NevadaPURE Is Terminated

    LAS VEGAS, May 9, 2018 /PRNewswire/ -- GB Sciences, Inc. (GBLX), the previously announced proposed acquisition of NevadaPURE, LLC, a Nevada limited liability company, by GB Sciences has been terminated. In accordance with the terms of the non-binding letter of intent signed between the parties and after the due diligence period (which was mutually extended by one week), GB Sciences and NevadaPURE, LLC mutually agreed not to proceed with the transaction. GB Sciences' Chairman of the Board and CEO John Poss said: "A nondisclosure agreement between the parties prevents GB Sciences from making extensive comments on the proposed transaction.

  • ACCESSWIRE5 months ago

    Marijuana Stocks for Investors in the Free Cannabis Investor Magazine

    MIAMI, FL / ACCESSWIRE / May 7, 2018 / Cannabis Investor Magazine , the leading industry investment magazine for cannabis investors, analysts, executives, entrepreneurs, and financial media, announced ...

  • ACCESSWIRE5 months ago

    GB Sciences is Exploring a Cannabis Therapy for Parkinson's, Analysts Review

    The company recently announced that it is planning to file an Exploratory IND and perform a Phase 0 Clinical Trial to gather valuable First-In-Human data on its proprietary cannabis-based therapies for the treatment of early to moderate Parkinson's disease. The GB Sciences' Exploratory IND program is designed to allow the company to make informed, data-driven choices in selecting and prioritizing the development of multiple, related drug compositions and formulations. Furthermore, the transaction also enables GB Sciences with access to three licenses from the state of Nevada for cultivation and production of marijuana along with the one for running a dispensary.

  • ACCESSWIRE5 months ago

    GVC Capital and Trickle Research Announce Presenter Schedule for Rocky Mountain MicroCap Conference II in Denver on April 24, 2018

    DENVER, CO / ACCESSWIRE / April 20, 2018 / GVC Capital LLC ("GVC") and Dave Lavigne at Trickle Research LLC ("Trickle Research") will host the Rocky Mountain MicroCap Conference II ...

  • PR Newswire5 months ago

    Exploratory IND Is Planned Using GB Sciences' Proprietary Mixtures of Botanical Compounds to Provide the Highest Efficacy for Patients

    LAS VEGAS, April 17, 2018 /PRNewswire/ -- GB Sciences, Inc. (GBLX), as previously reported, plans to file an Exploratory IND and perform a Phase 0 Clinical Trial to gather valuable First-In-Human data, to support clinical development decisions on prioritizing among multiple, related Parkinson's Disease ("PD") formulations.  GB Sciences has a patent application covering multiple, related PD-formulas that are based on complex mixtures of minor cannabinoids and terpenes from cannabis chemovars. In preclinical studies, GB Sciences has demonstrated that complex mixtures of cannabis-based compounds may provide greater clinical benefits than single compound treatments due to molecular synergies for the treatment of Parkinson's.

  • GB Sciences Pursues FDA-Registered, First-in-Human Trial of Cannabis-based Therapy for Parkinson's Disease
    PR Newswire5 months ago

    GB Sciences Pursues FDA-Registered, First-in-Human Trial of Cannabis-based Therapy for Parkinson's Disease

    LAS VEGAS, April 10, 2018 /PRNewswire/ -- GB Sciences, Inc. (GBLX) is planning to file an Exploratory IND and perform a Phase 0 Clinical Trial to gather valuable First-In-Human data on its proprietary cannabis-based therapies for the treatment of early to moderate Parkinson's disease ("PD").  The GB Sciences' Exploratory IND program is designed to allow the company to make informed, data-driven choices in selecting and prioritizing the development of multiple, related drug compositions and formulations. An Exploratory IND requires less pre-clinical data and offers a more flexible way to get essential information about potential drug development candidates than a more conventional early phase development program. Performing an FDA-Registered clinical trial, instead of a Nevada-based pilot trial as reported earlier, also translates to quicker entry into international markets with harmonized regulatory standards.

  • GB Sciences Completes Nanotechnology Transfer of Exclusively-Licensed, Cannabinoid-Based, Time-Released Neuropathic Pain Formula
    PR Newswire6 months ago

    GB Sciences Completes Nanotechnology Transfer of Exclusively-Licensed, Cannabinoid-Based, Time-Released Neuropathic Pain Formula

    LAS VEGAS, April 4, 2018 /PRNewswire/ -- GB Sciences, Inc. (GBLX) has completed the technology transfer for the manufacturing of time-released nanoparticles containing a cannabinoid-based therapeutic for neuropathic pain from the University of Seville. As announced in Q4 of 2017, GB Sciences has obtained the exclusive worldwide license to the intellectual property covering this time-released cannabinoid formulation from the University of Seville ("USE"), the Centro de Investigación Biomédica en Red de Salud Mental ("CIBERSAM") and the University of Cadiz ("UCA").

  • GB Sciences Signs Letter of Intent to Acquire NevadaPURE's Las Vegas Operations: Gaining $16 Million in Annualized Revenues
    PR Newswire6 months ago

    GB Sciences Signs Letter of Intent to Acquire NevadaPURE's Las Vegas Operations: Gaining $16 Million in Annualized Revenues

    LAS VEGAS, March 28, 2018 /PRNewswire/ -- GB Sciences, Inc. (GBLX) is extremely pleased to announce it has signed a letter of intent to purchase 100% of the ownership interests of NevadaPURE's Las Vegas operation for $28 million in cash and the assumption of approximately $5 million of outstanding liabilities. The annualized sales run rate of NevadaPURE is over $16 million based on its performance since adult use became legal in Nevada, making the purchase price only two times sales.  This sales multiple compares with GB's current price-to-annualized-sales multiple of 16, and a typical multiple of 60 or much more for publicly traded cannabis companies whose sales are similar to GB's.

  • GB Sciences Signs Letter of Intent to Acquire NevadaPURE's Las Vegas Operations: Gaining $16 Million in Annualized Revenues
    CNW Group6 months ago

    GB Sciences Signs Letter of Intent to Acquire NevadaPURE's Las Vegas Operations: Gaining $16 Million in Annualized Revenues

    GB Sciences Signs Letter of Intent to Acquire NevadaPURE's Las Vegas Operations: Gaining $16 Million in Annualized Revenues

  • PR Newswire6 months ago

    Research Projects Sales of Legal Cannabis Products to Accelerate This Year

    According to a report by Ameri Research Inc., the global legal cannabis market was valued at $14.3 billion in 2016 and is estimated to grow at a CAGR of 21.1% between 2017 to 2024, while reaching a value of $63.5 billion by 2024. The market is going through a period of robust growth because of increasing legalization and decriminalization of cannabis products across North America. Data by Arcview Market Research clarifies that growth of the legal cannabis industry are expected reaccelerate in 2018, as adult use sales ramp up in Canada, California, and Massachusetts along with medical sales in Florida.